|
|
 |
|
Viewing report
|
|
|
|
R&D Trends: Bipolar Disorders - Developments in Schizophrenia Dictate Trends in Diminutive Bipolar Disorders Pipeline
Datamonitor, April 2011, Pages: 75
Introduction
For the past 5 years R&D for new bipolar disorders drugs has been met with mixed success; while five drugs have progressed through the clinical pipeline and entered the market, four late-stage candidates have been discontinued. For four of the approved products, bipolar disorders represented an indication expansion. Alexza’s AZ-004 (loxapine) is currently the closest pipeline candidate to market
Features and benefits
- Analysis of key trends in the late- and early-stage drug pipeline for bipolar disorders.
- Identification of the target product profile for future bipolar disorders treatments.
- Summary of clinical trial design in bipolar disorders including exploration of how the design of clinical trials may develop in the future.
- Exploration of the future treatment in bipolar disorders including personalized medicine and treatment of cognitive impairment.
Highlights
- The bipolar disorders pipeline is sparse relative to other psychiatric markets. The diminutive size of the pipeline relative to the depression and schizophrenia pipelines indicates that bipolar disorders are considered less commercially attractive.
- The limited number of products in development reflects the well-established trend for developers of atypical antipsychotics to seek bipolar disorders as a secondary indication to schizophrenia. However, the time lag between an antipsychotic gaining approval in schizophrenia then bipolar disorders has narrowed in recent years.
- In the long term, ongoing research is expected to lead to personalized treatment of bipolar disorders. In particular, biomarker research has the potential to predict treatment response in patients. In addition, it is expected that research in schizophrenia may
inform development of cognitive treatments in bipolar disorders.
Your key questions answered
- How many drugs are in clinical development for the treatment of bipolar disorders? How does this compare to other psychiatric indications?
- Is bipolar depression or bipolar mania the most commonly investigated bipolar disorder indication in clinical trials?
- How is the treatment of bipolar disorders likely to evolve over the next 10 to 20 years?
- Since 2006, what proportion of late-stage bipolar disorder candidates have progressed through clinical development or been discontinued?
|
|
|
|
